Siana Nkya

Siana Nkya


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2018 in BMC Hematology
Verified
Journal Article
Open access
PDF file
JMJulie Makani
Julie Makani
FTFurahini Tluway
Furahini Tluway
AMAbel Makubi
Abel Makubi
DSDeogratius Soka
Deogratius Soka
SNSiana Nkya
Siana Nkya
BMBruno Mmbando
Bruno Mmbando
Africa has the highest burden of Sickle cell disease (SCD) but there are few large, systematic studies providing reliable descriptions of the disease spectrum. Tanzania, with 11,000 SCD births annually, established the Muhimbili Sickle Cell program aiming to improve understanding of SCD in Africa. We report the profile of SCD seen in the first 10 years at Muhimbili National Hospital (MNH). Individuals seen at MNH known or suspected to have SCD were enrolled at clinic and laboratory testing for SCD, haematological and biochemical analyses done. Ethnicity was self-reported. Clinical and laboratory features of SCD were documented. Comparison was made with non-SCD population as well as within 3 different age groups (< 5, 5–17 and ≥ 18 years) within the SCD population. From 2004 to 2013, 6397 individuals, 3751 (58.6%) SCD patients, were enrolled, the majority (47.4%) in age group 5–17 years. There was variation in the geographical distribution of SCD. Individuals with SCD compared to non-SCD, had significantly lower blood pressure and peripheral oxygen saturation (SpO2). SCD patients had higher prevalence of severe anemia, jaundice and desaturation (SpO2 < 95%) as well as higher levels of reticulocytes, white blood cells, platelets and fetal hemoglobin. The main causes of hospitalization for SCD within a 12-month period preceding enrolment were pain (adults), and fever and severe anemia (children). When clinical and laboratory features were compared in SCD within 3 age groups, there was a progressive decrease in the prevalence of splenic enlargement and an increase in prevalence of jaundice. Furthermore, there were significant differences with monotonic trends across age groups in SpO2, hematological and biochemical parameters. This report confirms that the wide spectrum of clinical expression of SCD observed elsewhere is also present in Tanzania, with non-uniform geographical distribution across the country. Age-specific analysis is consistent with different disease-patterns across the lifespan.

5 June 2020 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
SNSiana Nkya
Siana Nkya
LMLiberata Mwita
Liberata Mwita
JMJosephine Mgaya
Josephine Mgaya
HKHappiness Kumburu
Happiness Kumburu
MZMarco van Zwetselaar
Marco van Zwetselaar
JMJulie Makani
Julie Makani
Background: Sickle cell disease (SCD) is a blood disorder caused by a point mutation on the beta globin gene resulting in the synthesis of abnormal hemoglobin. Fetal hemoglobin (HbF) reduces disease severity, but the levels vary from one individual to another. Most research has focused on common genetic variants which differ across populations and hence do not fully account for HbF variation. Methods: We investigated rare and common genetic variants that influence HbF levels in 14 SCD patients to elucidate variants and pathways in SCD patients with extreme HbF levels (≥7.7% for high HbF) and (≤2.5% for low HbF) in Tanzania. We performed targeted next generation sequencing (Illumina_Miseq) covering exonic and other significant fetal hemoglobin-associated loci, including BCL11A, MYB, HOXA9, HBB, HBG1, HBG2, CHD4, KLF1, MBD3, ZBTB7A and PGLYRP1. Results: Results revealed a range of genetic variants, including bi-allelic and multi-allelic SNPs, frameshift insertions and deletions, some of which have functional importance. Notably, there were significantly more deletions in individuals with high HbF levels (11% vs 0.9%). We identified frameshift deletions in individuals with high HbF levels and frameshift insertions in individuals with low HbF. CHD4 and MBD3 genes, interacting in the same sub-network, were identified to have a significant number of pathogenic or non-synonymous mutations in individuals with low HbF levels, suggesting an important role of epigenetic pathways in the regulation of HbF synthesis. Conclusions: This study provides new insights in selecting essential variants and identifying potential biological pathways associated with extreme HbF levels in SCD interrogating multiple genomic variants associated with HbF in SCD.

18 June 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
EAEvans Xorse Amuzu
Evans Xorse Amuzu
FUFlorence Urio
Florence Urio
EDElliot Eli Dogbe
Elliot Eli Dogbe
PPPeter Ponsian
Peter Ponsian
SASuraj Yawnumah Abubakar
Suraj Yawnumah Abubakar
SNSiana Nkya
Siana Nkya
Background Prevalence of sickle cell disease (SCD) across African countries ranges between 1–3% and contributes up to 7–16% of under-five mortality. In order to bridge the gap in management and cognate research, the SickleInAfrica consortium was established in 2017 to facilitate collaboration among African nations in order to establish regionally relevant healthcare standards for SCD patients. This work utilised the SickleInAfrica platform to study the levels of HbF and F cells and their relationship with sickle cell disease clinical manifestations in Ghana, Nigeria and Tanzania. Methods This study enrolled 290 individuals with SCD aged five years and above who were confirmed to be at steady state and were hydroxyurea naïve. Clinical history was obtained using an interviewer-administered questionnaire. Haematological parameters were determined by an automated haematology analyser, while quantification of HbF and F cells was implemented by high-performance liquid chromatography and flow cytometry, respectively. Age-adjusted logistic regression was employed to assess the association of HbF with the clinical manifestations. Results The most reported complication of SCD, requiring management in a hospital setting is pain crises, ranging from 66–96% with the highest in Tanzania and lowest in Ghana. HbF and F cell parameters show significant association with transfusion rates, frequency of painful crises and episodes of febrile illness. Conclusion This work highlights important differences and similarities across SCD populations in the three countries. This is important especially in development of interventions in the light of personalised medicine.

3 February 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
Dr Mohamed Zahir Zahir AlimohamedDr Mohamed Zahir Zahir Alimohamed
Dr Mohamed Zahir Zahir Alimohamed
AMAneth David Mwakilili
Aneth David Mwakilili
KMKenneth Mbwanji
Kenneth Mbwanji
ZMZainab Karim Manji
Zainab Karim Manji
FKFrida Kaywanga
Frida Kaywanga
SNSiana Nkya
Siana Nkya
Human genetics research and applications are rapidly growing areas in health innovations and services. African populations are reported to be highly diverse and carry the greatest number of variants per genome. Exploring these variants is key to realize the genomic medicine initiative. However, African populations are grossly underrepresented in various genomic databases, which has alerted scientists to address this issue with urgency. In Tanzania, human genetics research and services are conducted in different institutions on both communicable and noncommunicable diseases. However, there is poor coordination of the research activities, often leading to limited application of the research findings and poor utilization of available resources. In addition, contributions from Tanzanian human genetics research and services are not fully communicated to the government, national, and international communities. To address this scientific gap, the Tanzania Society of Human Genetics (TSHG) has been formed to bring together all stakeholders of human genetics activities in Tanzania and to formally bring Tanzania as a member to the African Society of Human Genetics. This article describes the inauguration event of the TSHG, which took place in November 2019. It provides a justification for its establishment and discusses presentations from invited speakers who took part in the inauguration of the TSHG.

15 January 2022 in Hemato
Verified
Journal Article
Open access
PDF file
AFAnna Daniel Fome
Anna Daniel Fome
Raphael Z. SangedaRaphael Z. Sangeda
Raphael Z. Sangeda
EBEmmanuel Balandya
Emmanuel Balandya
JMJosephine Mgaya
Josephine Mgaya
DSDeogratias Mat Soka
Deogratias Mat Soka
BMBruno Mmbando
Bruno Mmbando
Hematological and biochemical reference values in sickle cell disease (SCD) are crucial for patient management and the evaluation of interventions. This study was conducted at Muhimbili National Hospital (MNH) in Dar es Salaam, Tanzania, to establish laboratory reference ranges among children and adults with SCD at steady state. Patients were grouped into five age groups and according to their sex. Aggregate functions were used to handle repeated measurements within the individual level in each age group. A nonparametric approach was used to smooth the curves, and a parametric approach was used to determine SCD normal ranges. Comparison between males and females and against the general population was documented. Data from 4422 patients collected from 2004–2015 were analyzed. The majority of the patients (35.41%) were children aged between 5–11 years. There were no significant differences (p ≥ 0.05) in mean corpuscular hemoglobin concentration (MCHC), lymphocytes, basophils, and direct bilirubin observed between males and females. Significant differences (p < 0.05) were observed in all selected parameters across age groups except with neutrophils and MCHC in adults, as well as platelets and alkaline phosphatase in infants when the SCD estimates were compared to the general population. The laboratory reference ranges in SCD at steady state were different from those of the general population and varied with sex and age. The established reference ranges for SCD at steady state will be helpful in the management and monitoring of the progress of SCD.

9 September 2022 in Frontiers in Pediatrics
Verified
Journal Article
Open access
SNSiana Nkya
Siana Nkya
BNBelinda J. Njiro
Belinda J. Njiro
DNDoreen Ngowi
Doreen Ngowi
DSDavid Solomon
David Solomon
FKFrida Kaywanger
Frida Kaywanger
JMJulie Makani
Julie Makani
Sickle Cell Disease (SCD) is a known public health burden in sub-Saharan Africa (SSA). The manifestation of SCD starts in early childhood and if not well-managed may lead to early death (before the age of 5 years). Understanding the underlying mechanisms that influence early SCD manifestation is of great importance for early disease and intervention management which will in turn, reduce both morbidity and mortality rates in children. One approach of achieving this is by establishing SCD birth cohorts that can be followed for a period of time (3–5 years) whilst documenting necessary information related to early childhood illnesses. To date, there are few SCD birth cohorts in Africa. To address this gap, we have established a birth cohort of babies with and without SCD (with sickle cell trait and healthy babies). These babies are followed up for 3 years with their study visits synchronized to the immunization schedule. During enrollment and follow-up visits, information on demographic, clinical, and laboratory parameters are collected. To date, we have enrolled a total of 341 babies with and without SCD. Out of these, a total of 311, 186, 133, 81, 44, and 16 babies have returned for their 1st, 2nd, 3rd, 4th, 5th, and 6th visits, respectively. We have collected both demographic and clinical information for these babies at enrollment and during follow-up. We have also utilized this platform to learn on the best approaches of establishing and maintaining a research birth cohort in an African context. We have analyzed the practical issues pertaining to the integration of the birth cohort with the immunization platform which seems to be the most effective and sustainable strategy for maintaining a birth cohort in our context.